Effectiveness and Safety of Dabigatran Rivaroxaban and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation

摘要

BackgroundThe introduction of non–vitamin K antagonist oral anticoagulants has been a major advance for stroke prevention in atrial fibrillation; however, outcomes achieved in clinical trials may not translate to routine practice. We aimed to evaluate the effectiveness and safety of dabigatran, rivaroxaban, and apixaban by comparing each agent with warfarin.